Business
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease CasesOGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensitivity and Genomic InsightsOGM Can Identify Actionable Disrupted Genes Across Rare Diseases SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) reported that 28 publications describing the utility of optical genome mapping (OGM) for analysis of rare diseases were release
About this update from Bionano Genomics, Inc.
[{"type":"image","alt":"Bionano Genomics","displaySize":"","headline":null,"caption":"Bionano Genomics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BL0NoL0PFOcUTHrfwl5LaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1","width":300,"height":61}},"lazy":false},{"type":"text","content":"Overall, studies show:","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"OGM Can Resolve Previously Unresolved Rare Disease Cases","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"OGM Can Serve as a Gold Standard Technique for Characterization of SVs ","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"OGM Can Complement Sequencing for Better SV Sensitivity and Genomic Insights","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"OGM Can Identify Actionable Disrupted Genes Across Rare Diseases","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":266,"olType":false},{"type":"text","content":"SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) reported that 28 publications describing the utility of optical genome mapping (OGM) for analysis of rare diseases were released in Q1 2026, representing an approximately 56% increase over last year. The total number of samples analyzed, 78, represents a 225% increase compared to the number analyzed in studies published in Q1 2025 (24). Publications describing OGM use in rare disease research come from institutions all around the world, including from Europe, Asia, South America, and the United States.","length":589,"tagName":"p"},{"type":"text","content":"These studies describe the ability of OGM to enable clinical researchers to identify, characterize and interpret relevant structural variants (SVs) often missed by traditional cytogenetic methods such as karyotyping, fluorescence in-situ hybridization (FISH) and chromosomal microarrays (CMA) as well as next-generation sequencing (NGS) and long-read sequencing (LRS). They encompass a broad range of conditions, including neurodevelopmental, neuromuscular, neurodegenerative, immunological, and malformation syndromes.","...